Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONCY $1.00 0.1800 +21.95%
ZIOP $3.32 0.2600 +8.50%
SRNE $4.22 0.2400 +6.03%
AEZS $1.12 0.0600 +5.66%
ONTX $4.86 0.2100 +4.52%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BIND $8.05 -0.8900 -9.96%
GALE $2.05 -0.1600 -7.24%
ARRY $3.59 -0.2800 -7.24%
APRI $1.48 -0.1000 -6.33%
ONTY $1.80 -0.1200 -6.25%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Cleveland Clinic, IBM Launch New Watson Project to Find New Treatment Options For Cancer Patients

(The Plain Dealer [Cleveland, OH]) Oct 29, 2014 - The Cleveland Clinic and IBM on Wednesday announced a new collaboration with Watson that is designed to help oncologists identify new cancer treatment options for their patients.
read article 



Rosetta Genomics Partners with Admera Health for the Commercialization of Current and Future Sequencing-Based Oncology Tests

(CNBC) Oct 30, 2014 - Rosetta Genomics Ltd. announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.
read article 



FDA Grants Kamada Orphan Drug Designation For the Treatment of Graft Versus Host Disease

(TheStreet) Oct 29, 2014 - Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat Graft-versus-host-disease (GVHD).
read article 



Clinical Practice Guidelines Address Multimodality Treatment For Esophageal Cancer

(STS) Oct 30, 2014 - The Society of Thoracic Surgeons (STS) has released new clinical practice guidelines for treating cancer of the esophagus and gastroesophageal junction (area where the esophagus meets the stomach).
read press release 



CHEST Lung Cancer Experts Present Policy Statement to CMS Committee on Coverage

(CHEST) Oct 30, 2014 - As the Centers for Medicare & Medicaid Services (CMS) Committee on Coverage studies the decision to cover lung cancer screening for eligible individuals, today’s Online First section of the journal CHEST published Components for High Quality Lung Cancer Screening: American College of Chest Physicians and American Thoracic Society Policy Statement.
read press release 



UTHealth Research Shows Mushroom Extract, AHCC, Helpful in Treating HPV

(UTHealth Houston) Oct 28, 2014 – A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston (UTHealth) Medical School.
read press release 



Researchers Discover New Gene Mutation to Improve Diagnosis and Treatment of Salivary Gland Cancer

(OICR [Canada]) Oct 29, 2014 - Researchers have identified a specific gene called PRKD1 that is mutated in the vast majority of patients with a specific type of oral salivary gland cancer.
read press release 



UMMS Study: Tanning Beds Widely Available On or Near College Campuses, Despite Cancer Risk

(UMMS Now/UMass Medical School) Oct 29, 2014 - Despite a high skin cancer risk, tanning beds are available on campus or in off-campus housing at nearly half of the nation’s top colleges, and access is frequently discounted or entirely free of charge, according to a new study from UMass Medical School published online Oct. 29 in JAMA Dermatology.
read article 



New Molecular Imaging Technology Could Improve Bladder-Cancer Detection, Researchers Say

(Stanford Medicine) Oct 29, 2014 - Researchers have developed a new imaging method that targets a protein known as CD47 in human bladder cancer. This technology may greatly improve cancer detection and enable more accurate surgeries.
read press release 



Breast and Colorectal Cancers Remain More Aggressive in Children

(American College of Surgeons) Oct 29, 2014 - Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base (NCDB) studies presented this week at the 2014 Clinical Congress of the American College of Surgeons.
read press release 



New Data on Fatigue From ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients With Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

(CNBC) Oct 30, 2014 - In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue and improve health-related quality of life in patients with advanced NSCLC cachexia.
read article 



Molecular Tumor Markers Could Reveal New Therapeutic Targets For Lung Cancer Treatment

(Yahoo! Finance) Oct 30, 2014 - Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
read article 



Lung Cancer Patients With Minimally Invasive Adenocarcinoma Have Comparable 97.7 Percent 5-Year Survival Rate as Patients With Adenocarcinoma In-Situ

(Yahoo! Finance) Oct 30, 2014 - Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS), according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
read article 



10 Years of Data Reveals Excellent, Sustained Local Control With Minimal Side Effects For Medically Inoperable, Early Stage Lung Cancer Patients

(Yahoo! Finance) Oct 30, 2014 - Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
read article 



Post-Operative Radiation Therapy Improves Overall Survival for Patients With Resected Non-Small Cell Lung Cancer

(Yahoo! Finance) Oct 30, 2014 - Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
read article 



Medicare Costs Analysis Indicates Need For Decreasing Use of Biopsies as Diagnosis Tool For Lung Cancer

(Yahoo! Finance) Oct 30, 2014 - Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
read article 



Patients at High-Risk For Lung Cancer Are More Likely to Receive Screening When Primary Care Provider Is Familiar With Guideline Recommendations

(Yahoo! Finance) Oct 30, 2014 - Patients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (LDCT) screening when their primary care provider is familiar with guideline recommendations for LDCT screening for lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
read article 



Update: New Melanoma Drug Shows Promise In Trial

(Forbes) Oct 29, 2014 - A new cancer drug benefited 51% of stage III and IV melanoma patients during a phase II trial, achieving complete response (total cancer disappearance) in 26% during the treatment period. That was all in just 16 weeks of treatment, suggesting this drug has great potential for treating certain cancers in the future.
read article 



Cord Blood Transplant: In Children, One Will Do

(Medscape Medical News) Oct 29, 2014 - It may seem intuitive that, in stem cell transplantation, two units of cord blood may bestow significantly better outcomes than one unit of cord blood. But at least in children, that may not be the case: the outcomes were similar after both.
read article (free registration required) 



Bristol Immunotherapy Shows Promise in Lung Cancer Trial

(Reuters) Oct 30, 2014 - Treatment of advanced squamous cell non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb Co's experimental immunotherapy nivolumab led to a one-year survival rate of 41 percent in a midstage clinical trial, according to data being presented at a medical meeting.
read article 



Most Internet Sources on Prostate Cancer Disagree with Expert Panel’s No-Screening Recommendation

(American College of Surgeons) Oct 27, 2014 - New study shows that two-thirds of health websites appearing on the first page of search results do not recommend against prostate cancer screening, as opposed to the US Preventive Services Task Force.
read press release 



Prostate Cancer Medications Linked with Increased Risk of Heart-Related Deaths in Men with Cardiovascular Problems

(Wiley) Oct 29, 2014 - A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.
read corporate press release 



Triphase, Celgene Extend Deal for IV Formulation of Marizomib and Bevacizumab for Glioblastoma

(Pharmaceutical Business Review) Oct 29, 2014 - Drug development firm Triphase Accelerator has extended its strategic collaboration with Celgene for a Phase I development program to explore combining an intravenous (IV) formulation of marizomib with bevacizumab in glioblastoma (GBM), an aggressive malignant primary brain tumor.
read article 



FDA Staff Recommends Limited Use of Daiichi's Blood Thinner

(Reuters) Oct 28, 2014 - U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function.
read article 



Lilly, Boehringer Ingelheim Revise Diabetes Alliance In Certain Countries

(RTTNews.com) Oct 29, 2014 - Boehringer Ingelheim and Eli Lilly and Company are changing the operational and financial structure of their diabetes alliance in certain countries, Eli Lilly said. The changes will be implemented starting January 1, 2015.
read article